

n 1188Ue

10-30-99

Food and Drug Administration Dockets Management Branch (HFA-305) 5630 Fishers Lane, #1061 Rockville, MD 20852

Dear Sir/Madam,

This is our written comment on Proposed Rule 21CFR Part 210, 211, 820 and 1271 (Docket No. 97N-484S) "Suitability Determination for Donors of Human Cellular and Tissue-Based Products", published in the Federal Register vol. 64, No. 189, September 30, 1999.

Proposed Rule 1271.85 on page 92705 reads: "The following list represent FDA's current thinking on the appropriate FDA-licensed, approved or cleared screening tests that should be used to adequately and appropriately reduce the risk of transmission of relevant communicable disease agents or diseases:

(3) HBV: FDA-licensed screening test for hepatitis B surface antigen (HBsAg)

On the page 92706 the proposed rule reads:
"In the case of HBV there are two types of screening tests: A test for
the surface antigen and a test for the core antibody".
Further on page 92706 the proposed rule reads:
"For example, a repeatedly reactive core antibody test for HBV, although
not required, would make the donor unsuitable"

FDA should consider the following addition to the Proposed Rule:

If the use of an FDA-cleared serological test for HBsAg is reported as NEGATIVE (NON-REACTIVE) and the use of an FDA-cleared serological test for Hepatitis B core antibody (HBcAb) is reported as POSITIVE (REACTIVE), the clarification of donor potential Hepatitis B infectivity and Hepatitis B immune status can be performed by using both of the following two FDA-cleared serological tests:

- a) HBcAb IgM and
- b) Hepatitis B surface Antibody (HBsAb)

## **Pacific Coast Tissue Bank**

2500-19 So. Flower Street • Los Angeles, Ca. 90007 • Ph# 213 745-5560 Fax# 213 745-3031

.

In the following serological picture:

HBsAg - NEGATIVE HBcAb - POSITIVE HBsAb - POSITIVE HBsAb - POSITIVE

donor has had Hepatitis B infection in the past which has resolved. Non-hepatic tissue from such donor can not transmit Hepatitis B and donor should be considered suitable. It must be mentioned that 95-99% of adults contracting hepatitis B infection progress to complete recovery with development of established protective antibody (HBsAb). Enclosed is a study published in The Lancet in 1974. This study was supported by a grant from National Heart and Lung Institute, Bethesda, Maryland and performed in collaboration with the Blood Bank Department of National Institute of Health

This study examined the risk of transfusing blood containing HBsAb. Since this study was performed prior to Hepatitis B vaccine being available, all donors with positive HBsAb had prior infection with Hepatitis B virus and by definition also had positive HBcAb. The study has found that HBsAb positive blood does not transmit Hepatitis B to the recipients.

Presence of HBcAb (IgG) is not a SCREENING TEST for Hepatitis B infectivity as the proposed rule states, but a HISTORICAL TEST indicating previous infection with Hepatitis B virus which in the vast majority of cases terminates in recovery and development of protective immunity.

Sincerely

Eli Gendler MD Medical Director Pacific Coast Tissue Bank the pueller MO

Tillman M. Moore MD Medical Director

Pacific Coast Tissue Bank

ATTACHMENT




Fig. 4-Five patients with insulinomas in whom there was a temporary rise in plasma-insulin levels in response to fish-insulin-induced hypoglycæmia.

See legend to fig. 2.

which confirmed the diagnosis in the four patients who had normal basal glucose levels after an overnight fast. Although partial suppression of insulin secretion in response to hypoglycæmia was seen in some patients, the plasma-insulin levels remained distinctly abnormal in all the patients studied. In some patients there was a paradoxical increase in insulin secretion during the test. The cause of this is uncertain, but fish insulin contains immunoreactive glucagon, and this may have stimulated insulin secretion.

Hypoglycæmia during a three-day fast has often been used as a diagnostic test for insulinomas, and is an indirect means of demonstrating impaired suppression of insulin secretion. It is not specific unless raised plasma-insulin levels are also demonstrated. Exercise during the fast helps to induce hypoglycæmia, but fish insulin can produce a more certain fall in plasma-glucose over a shorter period. If spontaneous hypoglycæmia has been documented, a positive fish-insulin suppression test is diagnostic of an insulinoma and a fast is unnecessary.

In a patient in whom fasting hypoglycæmia is suspected as a possible cause of a curious attack, the demonstration of normal suppression of insulin secretion during a fish-insulin test probably excludes the diagnosis of an insulinoma. Stimulation tests for insulinomas are not useful in this context, because false-negative results are common.5.6 A normal fish. insulin test will not exclude other causes of faung hypoglycæmia, and only a prolonged fast will def. nitely do this. However, most of the other cause of fasting hypoglycæmia in adults can be easily excluded by other means. Endocrine deficiencies of the pituitary or adrenal, and cirrhosis, are usually seven and clinically apparent before hypoglycæmia occurs The hypoglycæmia induced by the fish-insulin tex provides a stimulation test for cortisol and growth. hormone secretion, with increased plasma levels the end of the test.7 Hypoglycæmia induced by ethanol, sulphonylurea, or other drugs, may be unpected from the history, and self-administration of insulin usually induces circulating insulin antibodies Sarcomas causing hypoglycæmia are usually large, and can be detected by palpating the abdomen, or by chest X-ray. Thus a normal fish-insulin suppression test combined with clinical assessment and a free simple tests exclude virtually all causes of fasting hypoglycæmia in adults. These tests can be performed on outpatients, and are useful in situations in which fasting hypoglycæmia is a possible, but improbable cause of curious attacks.

We thank Prof. P. B. Beeson for his support; the part cians who kindly referred the patients; and Mrs C. Ponsfeet Mrs M. Phillips, and Mrs C. Uren for their assistance. Sa of the patients with insulinomas were reported in earlier states performed with Dr N. W. Oakley, Dr. J. D. N. Nabarro, and Miss P. C. Johnson. This study was supported by grace from the British Diabetic Association and Peel Medical Research Trust.

Requests for reprints should be addressed to R. C. T.

#### REFERENCES

1. Turner, R. C., Oakley, N. W., Nabarro, J. D. N. Metabolim, 1971

Zi, 111. Turner, R. C., Johnson, P. C. Lancet, 1973, i, 1483. Turner, R. C., Oakley, N. W., Nabarro, J. D. N. Br. med J. 1871.

- Albano, J., Ekins, R. P., Maritz, G., Turner, R. C. Acta code. Copenh. 1972, 70, 487. Fajans, S. S. Excerpta med. int. Congr. Ser. 1969, 172, 894.
   Marks, V., Samols, S. ibid. p. 864.

7. Turner, R. C. Hormone Mesab. Res. (in the press).

# RISK OF TRANSFUSING BLOOD CONTAINING ANTIBODY TO HEPATITIS-

SURFACE ANTIGEN

HARVEY J. ALTER RICHARD D. AACH PAUL V. HOLLAND F. BLAINE HOLLINGER JOSEPH L. MELNICK JERROLD J. LANDER JOHN M. WEILER

Department of Medicine, Washington University School of Medicine; Blood Bank Department, Clinical Conte, National Institutes of Health; Department of Violet and Epidemiology, Baylor College of Medicine; and Blood Resources Branch, Division of Blood Diseases and Resources, National Heart and Lung Institute

362 blood-transfusion recipients, whose Summary were initially negative Sera hepatitis-B antigen (HB,Ag), were prospective followed for clinical and serological evidence d exposure to hepatitis-B virus (H.B.v.) and for the development of hepatitis unrelated to H.B.V.

of the donor tained detect: recipients, 23 only 4 of thes to H.B.V. Base (anti-HB<sub>s</sub>) pr were consider these suscepti unit of blood with the 145 v no significant itis B (3/133 v 5/133 vs. 5/1 11/133 vs. 6/ taining detect of transmitting lacks this anti-

THE risk o has been mi universal testi gen (HB,Ag) mercial blood HB Ag-positiv post-transfusio This could b or other spec: virus (H.B.V.) current detec escape detect to and therefo In the latte circulating as infectious.9 HB, indicates the finding of a reason for accepted excl hepatitis.10,11

Despite th containing an studies perfor an increased blood; the is because the n small or beca data to assess the exclusion reduce blood donors have a techniques.10 prospective st order to deter taining anti-H transmitting h antibody.

Deugn of Stuc Studies were Washington Ur Baylor College in Houston, and

A normal fish. causes of fasting will denthe other causes in be easily excluleficiencies of the are usually severe oglycæmia occurs e fish-insulin test tisol and growth. plasma levels at emia induced in ugs, may be sus. -administration of insulin antibodies usually large, and ibdomen, or by isulin suppression ment and a few causes of fasting can be performed tuations in which , but improbable

support; the physind Mrs C. Pond in their assistance. Sarted in earlier studies D. N. Nabarro, and supported by grantand Peel Medica

sed to R. C. T



3, 1, 1483. D. N. Br. med J

ner, R. C. Acta con-

. 1969, 172, 894

e press).

BLOOD

HEPATITIS B

EN

VEY J. ALTER L V. HOLLAND PH L. MELNICK

t University S.c., at, Clinical Consonment of Virel C. Medicine; and B., od Diseases and Lung Institute

n recipients, who we ly negative ere prospective gical evidence as and for the first terms.

of the donor units received by these patients conuned detectable HB, Ag. Of the 362 transfusion recipients, 23 (6%) developed 25 episodes of hepatitis; only 4 of these 25 episodes were serologically related 10 H.B.V. Based on the absence of antibody to HB.Ag anti-HB,) prior to transfusion, 278 of the patients were considered susceptible to H.B.V. infection. Of these susceptible patients, 133 received at least one init of blood containing anti-HB, when compared with the 145 who did not receive anti-HB, there was no significant difference in biochemical or overt hepaitis B (3/133 vs. 1/145), in serological response to H.B.V. 5/133 vs. 5/145), or in hepatitis unrelated to H.B.V. 11/133 vs. 6/145). It is concluded that blood conuining detectable anti-HB, carries no increased risk of transmitting hepatitis B compared with blood which acks this antibody.

### Introduction

THE risk of developing post-transfusion hepatitis has been markedly reduced by the adoption of iniversal testing of donor bloods for hepatitis-B antigen (HB,Ag) and by decreased utilisation of commercial blood.1 However, despite the exclusion of HB Ag-positive blood donors, some HB Ag-positive most-transfusion hepatitis continues to occur. 1-4 This could be due to the administration of HB, Ag a other specific antigens associated with hepatitis-B virus (H.B.V.) in quantities below the threshold of current detection methods.44 HB,Ag could also escape detection if that antigen were complexed and therefore masked by antibody to it (anti-HB<sub>a</sub>). In the latter instance, one might detect only reulating anti-HB, in blood that is potentially meetious.9 In addition, since the presence of antiiiB indicates past exposure to the hepatitis-B virus, e finding of this antibody might be just as valid reason for donor exclusion as is the currently accepted exclusion based upon a history of clinical opatitis. 18,11

Despite these theoretical considerations, blood maining anti-HB, is still transfused and the few adies performed to date have failed to demonstrate a increased infectivity of such antibody-containing and; the issue, however, is not totally resolved cause the number of individuals followed has been nall or because the studies have lacked serological 14'4 to assess susceptibility to H.B.V. 19-14 Furthermore, he exclusion of donors with anti-HB, would severely stace blood availability, since 5-20% of volunteer lining have anti-HB, detectable by present, sensitive niques.10 We have combined data from three tespective studies of post-transfusion hepatitis in ider to determine more clearly if donor blood conaming anti-HB, carries a significantly greater risk of cosmitting hepatitis B than blood which lacks this - inody,

### Patients and Methods

was of Studies

1 these were performed in three medical centres: the congron University Medical Center in St. Louis, the College of Medicine-Ben Taub General Hospital Houston, and the National Institutes of Health Clinical

Center in Bethesda. The designs of these studies have previously been described. Patients were assessed at the Washington University and the Ben Taub General Hospital beginning August, 1971, and at the Clinical Center Blood Bank beginning February, 1970. All patients successfully completed a six-month follow-up by November, 1973.

The Washington University study and the Clinical Center Blood Bank study followed cardiovascular-surgery patients, while the Baylor study followed a randomised sample of general-surgery patients who received blood-transfusions at Ben Taub General Hospital. The three studies are very comparable in design and are summarised in table 1. All donor units were tested for antigen and antibody, and recipients were followed at least every two weeks for three months and every month thereafter for three months. Washington University patients were followed every two weeks for six months. Patients were followed every two weeks for six months. Patients were excluded if they received transfusions on more than one occasion or if they received blood derivatives other than plasma, red cells, or whole blood.

### Definitions

Hepatitis was diagnosed when, between two and twentysix weeks following transfusion, alanine aminotransferase (S.G.P.T.) and/or aspartate aminotransferase (S.G.O.T.) rose to at least 2 times the upper limit of normal on 2 successive occasions at least a week apart, and when there was no other obvious explanation for the enzyme elevation. Icterus was defined as a bilirubin greater than 2 mg. per 100 ml. Hepatitis B was diagnosed when, during an episode of hepatitis, HBBAg was detected, and/ or the patient developed antibody seroconversion. Seroconversion was the de-novo appearance, and persistence, of anti-HBs twenty-one or more days after transfusion in a patient having no pre-existing antibody to the hepatitis-B antigen. Anamnestic response was a fourfold or greater rise of anti-HBs occurring within fourteen days following transfusion in a patient with pre-existing antibody. Serological response only was defined as seroconversion, or anamnestic response, or development of HBsAg in a patient who did not develop enzyme elevations indicative of hepatitis. Exposure was measured by development of hepatitis B and/or serological response to H.B.V.

## Technique

All donors in this study were tested for HB<sub>8</sub>Ag by counterelectrophoresis <sup>15,16</sup> prior to transfusion. After transfusion, stored sera from these donors were retested by radioimmunoassay. At Washington University and at Baylor subsequent testing was performed by double-antibody radioimmunoassay (R.I.A.-D.A.) <sup>17-19</sup> and by solid-phase radioimmunoassay (Ausria). At the Clinical Center most specimens, but not all, were retested by Ausria. Patients who were HB<sub>8</sub>Ag-positive prior to transfusion or who received blood containing HB<sub>8</sub>Ag were excluded from analysis in this report.

Anti-HBs was measured by R.I.A.-D.A. <sup>18,20</sup> and by passive hæmagglutination (P.H.A.).<sup>22</sup> These methods have recently been compared.<sup>23</sup> Washington University initially tested for anti-HBs by R.I.A.-D.A. and confirmed positives by P.H.A.; Baylor screened for antibody by P.H.A. and confirmed positives by R.I.A.-D.A. The Clinical Center Blood Bank tested for antibody by R.I.A.-D.A. initially in the study and by P.H.A. later.

Statistical analysis was performed by Dr Marian Fisher of the Biometrics Research Branch, National Heart and Lung Institute, using Fisher's exact test, two tails. Statistical significance in this study is defined as a p value of 0.05 or less.

#### Results

362 patients whose pre-transfusion sera were all initially HB<sub>s</sub>Ag-negative were followed for six months after transfusion. Sera from all of their donors were tested for HB, Ag and anti-HB. Table 1 shows the number of patients and the average number of units received per patient at each participating centre. The proportion of donors with antibody ranged from 9% at the Clinical Center to 15% at Ben Taub, whereas the proportion of recipients with pre-transfusion antibody ranged from 10% to 29%...

Table II provides the clinical and serological response to blood-transfusion in the 362 blood recipients. Among these patients, 25 episodes of hepatitis occurred, 4 of which were ascribed to type-B hepatitis. 2 patients had two distinct episodes of hepatitis-a short-incubation, non-type-B, anicteric illness, and a subsequent long-incubation, HB, Agpositive, icteric illness. 7 additional patients had a serological response to H.B.V. without biochemical evidence of hepatitis; 1 developed HB, Ag alone, 5 had seroconversion, and I had an anamnestic response. All 4 cases of HB, Ag-positive hepatitis were icteric compared with only 5 of 21 non-B hepatitis cases. There were no fatalities attributable to hepatitis in any of the patients followed.

TABLE I-CHARACTERISATION OF DONORS AND PATIENTS IN EACH STUDY CENTRE (ALL DONOR UNITS WERE NEGATIVE FOR HB-Ag\* AND WERE TESTED FOR ANTI-HB.)

Participating centre	No. of recipients followed six months	Average no, of donor units transfused per patient	Com- mercial blood (%)	Donors anti- HB, positive (%)	Recipients anti-HB <sub>s</sub> positive before transfusion (°a)	
Washington University Medical Center	105	11-3	0	11	22	
Baylor-Ben Taub General		11.2	Ü	11	22	
Hospital Clinical Center	208	2.8	15+	15	29	
Blood Bank	49	18-5	0	9	10	

<sup>\*</sup> All donor units were tested by counterelectrophoresis prior to transfusion; subsequently at Washington University and at Baylor all units, and at the Clinical Center most units, were retested by radioimmunoassay.

† 15% of the blood was obtained from a commercial blood-bank service but only one-fourth of these donors were paid.

We first analysed the entire recipient population (362 patients) in order to compare the clinical and serological outcome in those who received antibodycontaining blood with those who did not (table 11). There was no significant difference in measured H.B.V. exposure (5/172 vs. 5/190) nor in hepatitis unrelated to H.B.V. (13/172 vs. 8/190). Patients were then analysed separately according to whether or not they had anti-HB, prior to transfusion. 278 recipients did not have pre-existing anti-HBs; 145 of these recipients received only blood which lacked anti-HB, while 133 received at least one unit of blood containing anti-HB. When these groups were compared there was again no significant difference in measured H.B.V. exposure (5/145 vs. 5/133), in hepatitis B (1/145 vs. 3/133) or in hepatitis unrelated to H.B.v. (6/145 vs. 11/133).

84 patients had antibody to HB, Ag at the time of transfusion. 4 of these patients developed hepatitis, but none was serologically related to H.B.V. An anamnestic serological response to H.B.V. was observed in only 1 of the recipients with pre-existing anti-HB; that patient received blood containing anti-HB.

Among the 362 recipients in this study there were 21 episodes of hepatitis in which neither HB Ag nor anti-HB, could be demonstrated. These non-type-B cases showed no significant association with the presence or absence of pre-existing anti-HB, in the recipient or with the presence or absence of anti-HB in donor blood.

35 additional susceptible patients were followed by the Clinical Center Blood Bank. They were not included in the preceding analysis because greater than 90%, but not all, of their donor sera were tested for anti-HB.

All donors were tested for HB, Ag and were found to be negative. Each of these 35 patients received n least one unit of blood containing anti-HB. A negative control group for these patients cannot be presented because of the uncertain antibody status of untested donors. None the less, among these 35 additional recipients of blood containing anti-HB, none developed type-B hepatitis or serological response to H.B.V.; 2 developed hepatitis unrelated to H.B.V.

### Discussion

Seeff et al.,14 in a preliminary report of a study of over 2000 blood recipients, found that the risk of

TABLE II-CLINICAL AND SEROLOGICAL RESPONSE OF RECIPIENTS TO BLOOD WHICH CONTAINED OR LACKED ANTI-HE

Pre- transfusion serological status of recipient	Total no. of recipients	Donor blood contains:		No. of recipients	Total cases of	Confirmed exposure to H.B.V.				
						Total hepatitis-B	Serological response only		Total hepatitis-B	non-type-I
		HB,Ag	Anti-HB,		hepatitis	cases*	HB <sub>4</sub> Ag	Anti-HB <sub>4</sub>	exposure	
No HB <sub>s</sub> Ag or anti-HB <sub>s</sub>	278		-	145	7†	1 (1)†	1	3	5	6 (0)1
		_	_	133	14†	3 (3)†	0	2	5	11 (4)*
Pre-exist- ing anti- HB, only	84			45	2	0	0	0	0	2 (1)
		-		39	2	0	0	1	1	2 (0)
Totals .	362			362	25	4 (4)	1	6	11	21 (5)
			!					7		

<sup>\*</sup> Numbers in parentheses indicate numbers of total cases which were icteric.

developing receiving a HB. (14% risk after 1 or antibod less hepatit contained c

Goldfield of anti-HI 103 control nor HB, Ag did not de transfusion 37 recipien recipients c that antibo risk of tran the pre-tra was not sta bility to H.: transfusion not given a blood to el or to cause be ascertain

The pres developmer of serologic of these day was initiall presence of When the neither the serological c in those tra did not reco lack of stati those patier. ably suscep pre-existing

No cases occurred ar anti-HB, in among the Although tl nificant, the which indic in patients unusual.

The total Was 6.4%. hepatitis B; telated to H ship betwee and the prethe recipien

We conch the risk of e ment of H fusion of ani greater than of blood wh do not supp anti-HB.

This work s

<sup>† 2</sup> episodes of hepatitis were diagnosed in each of 2 patients; the first episode in each patient was non-type-B and the second was type-B he

i and ibodyole 11). H.B.V. related :n anaey had lid nor ipients: iile 133 ti-HR gain no <posure</p> 3/133),133).

IB. :re were LAg nor 1-type-B vith the in the anti-HB.

time of

epatitis,

v. An

bserved

nti-HB.:

owe a not inater than ested for

ere found :ceived at A negat be prestatus of 35 addi-HB, none sponse to H.B.V.

study of e risk of

non-type-B hepatitis.

6 (0) 11:4

2.1

2.0

e-B hepanii

developing overt or biochemical hepatitis B after receiving at least one unit of blood containing anti-HB, (1.4%) was not significantly greater than the risk after receiving blood without detectable antigen or antibody (0.6%); both groups had significantly less hepatitis than a third group receiving blood which contained only HB, Ag (13.7%).

Goldfield et al.24 prospectively studied 29 recipients of anti-HB,-containing, HB,Ag-negative blood and 103 controls who received blood with neither anti-HB. nor HBsAg; recipients of antibody-containing blood did not demonstrate an increased frequency of posttransfusion hepatitis. Gocke and Panick 12 compared 37 recipients of anti-HB<sub>a</sub>-containing blood with 136 recipients of anti-HB,-negative blood, and concluded that antibody-containing blood carried no increased risk of transmitting hepatitis B. In all three studies, the pre-transfusion antibody status of the recipients was not stated and therefore their presumed susceptibility to H.B.V. was unknown. In addition, the posttransfusion serological response of the patients was not given and thus the ability of anti-HB,-containing blood to elicit an HB, Ag response without hepatitis or to cause seroconversion without disease could not

The present study provides data not only on the development of hepatitis, but also on the development of serological response to H.B.v., and permits analysis of these data in terms of whether or not the recipient was initially susceptible to H.B.V. as judged by the presence of anti-HB, in the serum before transfusion. When the entire patient population was analysed, neither the risk of hepatitis B nor the frequency of serological exposure to H.B.V. was significantly greater in those transfused with anti-HB, than in those who did not receive antibody-containing blood. A similar lack of statistical association was observed when only those patients without pre-existing antibody (presumably susceptible patients) or when only patients with pre-existing antibody were analysed.

No cases of biochemical or overt hepatitis B occurred among the 84 recipients with pre-existing anti-HB, in contrast to the 4 cases which developed among the 278 presumably susceptible recipients. Although these differences are not statistically significant, they are consistent with previous studies 25,26 which indicate that anicteric or icteric hepatitis B in patients with pre-existing anti-HB, is extremely

The total hepatitis risk for patients in this study was 6.4%. Only 1.1% of recipients developed hepatitis B; hence only 16% of the total hepatitis was telated to H.B.V. As expected, there was no relationsup between the frequency of non-type-B hepatitis and the presence of anti-HB, in either the donor or ne recipient prior to transfusion.

We conclude from our data and other studies that ne tisk of exposure to hepatitis-B virus or of development of HB, Ag-positive hepatitis following transfusion of anti-HB,-containing blood is not significantly deater than that observed following the transfusion I blood which lacks detectable anti-HBs. The data in not support exclusion of donor blood containing ent-HBU

his work was supported in part by contracts NIH-NHLI-

70-2231 and NIH-NHLI-71-2353 from the National Heart and Lung Institute. We thank Miss Patricia Clay, Mr Jerry Chervitz, Mrs Loma Coday, Mrs Susan Fallek, Mr James McAdam, Mrs Shirley Snowe, Ms Karen Landry, Ms Melinda Freeman, Dr Marian Fisher, and Dr Robert Purcell for technical assistance.

Requests for reprints should be addressed to J. M. W., Building 31, Room 5A-11, Blood Resources Branch, Division of Blood Diseases and Resources, National Heart and Lung Institute, Bethesda, Maryland 20014, U.S.A.

#### REFERENCES

- 1. Alter, H. J., Holland, P. V., Purcell, R. H., Lander, J. J., Feinstone, , Morrow, A. G., Schmidt, P. J. Ann. intern. Med. 1972, S. M., 77, 691.

- T7, 691.
   Gocke, D. J. J. Am. med. Ass. 1972, 219, 1165.
   Koretz, R. L., Klaus, D. R., Ritman, S., Damus, K. H., Gitnick, G. L. Lancer, 1973, ii, 694.
   Hollinger, F. B., Aach, R. D., Gitnick, G. L., Roche, J. K., Melnick, J. L. New Engl. J. Med. 1973, 289, 385.
   Holland, P. V., Aiter, H. J., Purcell, R. H., Walsh, J. J., Morrow, A. G., Schmidt, P. J. in Australia Antigen (edited by J. E. Prier).
- Baltimore, 1973.
  6. Roche, J. K., Stengle, J. M. Transfusion, 1973, 13, 258.
- Barker, L. F., Shulman, N. R., Murray, R., Hirschman, R. J., Ratner, F., Diefenbach W. C. L., Geller, H. M. J. Am. med. Ass. 1970, 211, 1509.
- Hollinger, F. B., Werch, J., Melnick, J. L. New Engl. J. Med. 1974, 290, 1104.
- 9. Ashe, W. K., Notkins, A. L. Proc. natn. Acad. Sci. U.S.A. 1966, 56, 447
- 10. Szmuness, W., Prince, A. M., Brotman, B., Hirsch, R. L. J. infect.
- Szmuness, W., Prince, A. M., Brotman, B., Hirsch, R. L. J. inyett. Dis. 1973, 127, 17.
   Lewis, T. L., Alter, H. J., Chalmers, T. C., Holland, P. V., Purcell, R. H., Alling, D. W., Young, D., Frenkel, L. D., Lee, S. L., Lamson, M. E. New Engl. J. Med. 1973, 289, 647.
   Gocke, D. J., Panick, J. M. in Hepatitis and Blood Transfusion (edited by G. N. Vyas, H. A. Perkins, R. Schmid); p. 319. New York 1972.
- York, 1972. Caggiano, V. ibid. p. 323.
   Seeff, L. B., Zimmerman, H. J., Wright, E. C., Members of Cooperative Study Group. Gastroenterology 1973, 84, 893.
   Gocke, D. J., Howe, C. J. Immun. 1970, 104, 1031.
   Alter, H. J., Holland, P. V., Purcell, R. H. J. Lab. clin. Med. 1971, 77, 1000.
- 77, 1000
- 17. Aach, R. D., Grisham, J. W., Parker, C. W. Proc. natn. Acad. Sci. U.S.A. 1971, 68, 1056.
- 18. Hollinger, F. B., Vorndam, V., Dreesman, G. R. J. Immun. 1971,
- 107, 1099.
   19. Hollinger, F. B. Hepatitis in Manual of Clinical Microbiology; chapter 91. American Society for Microbiology, Washington, D.C.

- chapter 91. American Society for Microbiology, washington, D.C. (in the press).

  20. Ling, C. M., Overby, L. R. J. Immun. 1972, 109, 834.

  21. Hacker, E. J., Aach, R. D. J. Am. med. Ass. 1973, 223, 414.

  22. Vyas, G. R., Shulman, N. R. Science, 1970, 170, 332.

  23. Weiler, J. M., Grady, G. F. Transfusion (in the press).

  24. Goldfield, M. in Transmissible Diseases and Blood Transfusion (edited by T. J. Greenwalt and G. A. Jamison). New York (in the
- Lander, J. J., Giles, J. P., Purcell, R. H., Krugman, S. New Engl. J. Med. 1971, 285, 303. 26. Greenberg, H. B., Gocke, D. J. J. infect. Dis. 1971, 123, 356.

# SEASONAL OCCURRENCE OF COMPLEX VENTRICULAR SEPTAL DEFECT

DONALD C. FYLER KENNETH I. ROTHMAN Department of Epidemiology, Harvard School of Public Health, and Department of Cardiology, Children's Hospital Medical Center, Boston, U.S.A.

The seasonal occurrence of births of Summary children with ventricular septal defects (V.S.D.) was examined for a series of 302 cases from New England. The overall series showed a moderate peak in the summer, which was entirely attributable to a strong tendency for complex v.s.p. to occur in summer. Complex v.s.d. occurred 4.4 times more frequently in urban counties than rural counties, and the seasonal trend was strongest in urban areas. The seasonal peak was not associated with birth-weight,



U.S. POSTAGE
PAID
LOS ANGELES.CA
90015
NOV 05. 99
AMOUNT

0000

\$3.20

FROM PACIFIC COAST TISSUE BANK

2500-19 So. Flower St,

Los Angeles, CA. 90007

TO: Food and Drug Administration Dockets Management Branch (HFA-305) 5630 Fishers Lane, #1061 Rock Ville, MO 20852

CERTIFIED

Fold at line over top of envelope to the right of the return address